-
Mashup Score: 16A TriaL ComparIng the EffectiVEness and ToleraBility of MEdicaTions in Older Adults with STablE Angina and Multiple ChRonic Conditions: LIVE BETTER - 5 month(s) ago
Coronary artery disease (CAD) leading to stable symptoms (i.e., stable angina) is a leading contributor to death and disability among older adults with multiple chronic conditions. Treatment options for stable angina include both medications and invasive procedures, without any difference in rates of death or heart attacks across the different treatment approaches. Current guideline recommendations suggest that doctors should first treat patients with medications to improve symptoms from stable angina,
Source: www.pcori.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
Monday, September 11, 2023; 12:00 – 1:00 pm ET PFA Opens: September 6, 2023 Letter of Intent Deadline: October 3, 2023; 5:00 p.m. ET Letter of Intent Status Notification: October 31, 2023 Application Deadline: January 9, 2024; 5:00 p.m.
Source: www.pcori.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Interested in learning more? Join a Town Hall today at 12 p.m. EST https://t.co/nz4moJbbqi https://t.co/YXIYOq1km8
-
-
Mashup Score: 1Homepage | PCORI - 2 year(s) ago
The PCORI Strategic Plan A Bold Vision for Addressing Healthcare Challenges Generating Evidence to Achieve More Efficient, Effective, and Equitable Health Care and Improve Health for All Learn More Our Impact and Evidence You Can Use …
Source: www.pcori.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Not to be missed 👉 Patient-Centered Outcomes Research Institute (PCORI) #VBHC #PROM #HRQoL https://t.co/ZBwjRPZfnf
-
-
Mashup Score: 26PRECIDENTD (PREvention of CardIovascular and DiabEtic kidNey disease in Type 2 Diabetes) - 3 year(s) ago
Heart disease is one of the major causes of illness and death in type 2 diabetes mellitus. Type 2 diabetes affects over 32 million Americans. Of this group, approximately 20 million people also have heart disease or are at very high risk for heart disease. Recent large studies have shown that two new classes of diabetes medications, called sodium-glucose cotransporter-2 inhibitors (SGLT2i) and…
Source: www.pcori.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @cpcannon: Cool new study coming! Comparison of SGLT2 vs. GLP-1RA vs. both! https://t.co/lk3TzSNzOW
-
-
Mashup Score: 2Second-Line Therapies for Patients with Type 2 Diabetes and Moderate Cardiovascular Disease Risk - 3 year(s) ago
Health Condition: Type 2 diabetes in patients who have a moderate risk for heart disease, defined as a 2 to 3 percent chance of having a heart attack or stroke, or dying in a given year. Importance: Type 2 diabetes is one of the most common and serious chronic health conditions in the United States. Keeping blood sugar levels in a safe range is important for preventing long-term complications of…
Source: www.pcori.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
RT @PCORI: Congratulations to @RozalinaMD @MayoClinic for study funding approval. Find study info here. https://t.co/nGz4iSvRC2
-
-
Mashup Score: 0Advisory Panel Openings - 3 year(s) ago
How to Submit a Third-Party NominationPCORI accepts third-party nominations for its advisory panels. To make a nomination, an individual or organization should send a letter of support to the individual they are nominating. Before making a nomination, we encourage nominators to review our application fields for guidance on presenting as robust a portrait of the nominee(s) as…
Source: www.pcori.orgCategories: Geriatrics, Latest HeadlinesTweet-
One of the ways PCORI seeks to bring voices from across the healthcare community into its work is through the PCORI Advisory Panels. Applications are now open for all 5 Advisory Panels. Learn more and apply: https://t.co/s4cLbBuI8f via @PCORI
-
-
Mashup Score: 0Advisory Panel Openings - 3 year(s) ago
We are now accepting nominations and applications for our advisory panels.
Source: www.pcori.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
One of the ways PCORI seeks to bring voices from across the healthcare community into its work is through the PCORI Advisory Panels. Applications are now open for all 5 Advisory Panels. Learn more and apply: https://t.co/JM8gOxER3t via @PCORI
-
-
Mashup Score: 0Advisory Panel Openings - 3 year(s) ago
We are now accepting nominations and applications for our advisory panels.
Source: www.pcori.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
As a member of the @PCORI Board of Governors, input from our key stakeholders is essential to generating and disseminating the best evidence. Please consider applying to one of our advisory panels (due Mar 31 '21). Details here: https://t.co/vCuGZ2q5q6
-
-
Mashup Score: 0Advisory Panel on Rare Disease - 4 year(s) ago
The Advisory Panel on Rare Disease will advise and provide recommendations to PCORI’s Board of Governors, Methodology Committee, and staff on the conduct of patient-centered comparative clinical effectiveness research in rare diseases and on coordination and engagement with the rare disease resea
Source: www.pcori.orgCategories: Latest Headlines, Rare DiseaseTweet-
Because of her unique perspective on #healthcare, Danielle Boyce, NORD Dir. of Research Tech, has been selected for @PCORI’s Advisory Panel on #RareDisease. The goal is to help patients & those who care for them make better informed health care decisions. https://t.co/hA1Mq9NobL
-
-
Mashup Score: 0PCORI approves $23 million for seven COVID-19 research studies - 4 year(s) ago
WASHINGTON, DC — In response to the coronavirus pandemic, the Patient-Centered Outcomes Research Institute (PCORI) has approved $22.6 million in funding for seven studies assessing various health care approaches to improve outcomes among people infected by the novel coronavirus and lessen the effects of COVID-19 on patients, health care workers and communities.
Source: www.pcori.orgCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@PCORI approves $23 million for seven #COVID19 19 research studies https://t.co/f9Y94PfLXG #remotemonitoring
-
First patient was randomized in the Live Better Trial From Inova: @ISHVnews @InovaHealth Amazing team effort by the Inova esearch team: Bravo 👏👏👏 @behnam_tehrani @mw_sherwood @_WayneBatchelor @MichaelGNanna @jennifer_rymer @Ajar_Kochar 👇👇 https://t.co/Chc8jxacxE